Patient description: A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow: A wellbeing, well-nourished man, non-icteric, cooperative and alert Weight: 73 kg Height: 177 BP: 120/80 HR: 90/min RR: 22/min Hgb: 13 g/dl WBC: 8000 /mm3 (Neutrophil: 2700/mm3) Plt: 300000 /ml AST: 40 U/L ALT: 56 U/L Alk P: 147 U/L Bill total: 1.2 mg/dl ESR: 120 mm/hr MPO-ANCA: 153 EU

Clinical trial eligibility criteria: eligible ages (years): 18.0-105.0,  PreDiabetes Pre Diabetes Prediabetic State Type2 Diabetes Type2 Diabetes Mellitus Overweight Obese Signed informed consent form. 2. Male or female aged ≥18 years on the day of screening. 3. Female subjects of childbearing potential must be on non-oral contraceptives, postmenopausal or sterile. 4. Prediabetes or newly diagnosed T2D (not on blood sugar lowering drugs) defined as HbA1c levels: ≥42 to ≤57 mmol/mol (≥6.0 to ≤7.5%-according to DCCT). 5. Body mass index (BMI) >25 kg/m2 and > or = 40 kg/m2. 6. Stable weight for 3 months (+/-5 kg). 7. No extreme changes in diet for the last 6 months such as anorexia, bulimia, etc. 8. Subject must be able and willing to attend all scheduled visits and comply with all study procedures with no planned holiday longer than 2 weeks during the 12 weeks of treatment  Diagnosed with type1 diabetes/Latent Autoimmune Diabetes in Adult (LADA) or secondary diabetes, as part of medical history or confirmed by laboratory test. 2. Previous or current Metformin treatment or other glucose reducing drug therapy within 3 months before screening visit. 3. Previous or current statin treatment or other blood lipid (LDL) reducing drug therapy, within 12 months before screening visit. 4. Previous or current medication known to cause weight loss or weight gain, such as systemic corticosteroids, thyroid hormones or Estrogen, within 1 month before screening visit. 5. Subjects who stopped smoking within 6 months before screening visit. 6. Diagnosed with chronic somatic diseases, except for obesity and treatment naive T2D, that in the opinion of the investigator may therefore affect metabolic and /or intestinal function (e.g. inflammatory bowel disease, intestinal dysfunction, pancreatic dysfunction, other causes of malabsorption, recent (past 6 months) neoplastic disease. 7. Any history of myocardial infarction or stroke within the 6 months before screening visit. 8. Anemia, donated blood or other major blood loss within 3 months from screening visit that in the opinion of the clinician may interfere with the study. 9. Pregnancy or breast feeding. 10. Allergies to silicon dioxide. 11. A diagnosed state that requires use of vitamin and/or mineral supplements during the study. 12. Previous major gastric surgery that may affect the study outcome, such as bariatric surgery. 13. Ongoing or unstable kidney condition with moderate to great reduction in glomerular filtration rate < 90 ml/min (GFR) that may affect metabolic parameters during the trial. 14. Ongoing or unstable liver condition that may cause changes in liver enzymes exceeding 2x upper normal levels. 15. Psychiatric or cognitive disorder and/or behavioral problems which in the opinion of the clinician may interfere with the study. 16. History of or ongoing alcohol or drug addiction. 17. Participation in any study involving an investigational drug or medical device within the past 30 days before the screening visit. 18. Belongs to a vulnerable population or has any condition such that his/her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner). 19. Is a relative of the Investigator or an employee at the clinical study site